Latest Commercialization News

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

Arafura Rare Earths Limited has acknowledged a breach of ASX Listing Rule 15.7 following premature media disclosure of a $200 million investment commitment from the National Reconstruction Fund Corporation. The company outlines corrective steps to prevent future compliance lapses.

Alterity Therapeutics is poised to release topline data from its pivotal ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy by February 2025, while managing a cash balance of A$4.54 million amid ongoing research expenses.

BOD Science has executed an asset sale deed transferring critical intellectual property rights to Optimus Salvus, marking a pivotal step in its Deed of Company Arrangement process.

Merchant House International Limited reports the completion of its Tianjin asset sale and the cessation of AMI operations, signaling a strategic wind-up and delisting plan.

Altamin Limited has completed the acquisition of Appian Italy’s 29.85% stake in Vedra Metals, gaining 100% ownership of the Gorno Project and positioning itself for streamlined development or sale.

IDT Australia has finalized a $20 million asset-based loan facility with ScotPac, replacing its previous $4.7 million NAB facility, to support its expanding sales pipeline and recent contract wins.

Multistack International Limited reported a net cash outflow from operating activities of $72,916 for the December 2024 quarter but ended with robust cash reserves of $975,608. Despite ongoing negative cash flows, the company remains confident in sustaining operations through secured financing and strategic asset acquisitions.

TMK Energy has successfully doubled its pilot production capacity at the Gurvantes XXXV Coal Seam Gas project and inked an early commercialisation deal to supply gas for power generation, positioning itself as a pioneer in Mongolia's emerging CSG sector.

Clarity Pharmaceuticals has secured a second FDA Fast Track Designation for its 64Cu-SAR-bisPSMA diagnostic agent, aiming to revolutionize prostate cancer imaging and speed regulatory approval.

Respiri Limited reports a standout December quarter marked by a 67% surge in patient program enrolments and robust revenue growth, bolstered by strategic acquisition synergies from Orb Health. The company is poised for further expansion in 2025 amid promising contract negotiations and evolving US healthcare reimbursement policies.

Adisyn Ltd has successfully raised $10 million through a heavily oversubscribed placement, signaling strong institutional confidence in its graphene-enhanced semiconductor technology. The capital will accelerate development, commercial partnerships, and operational scaling.